According to the latest market research, the scleroderma therapeutics market, which stood at USD 2.55 million in 2024, is projected to reach USD 3.84 million by 2032, growing at a CAGR of 5.28% over the forecast period of 2025–2032. This growth is largely driven by an increasing prevalence of autoimmune conditions such as systemic sclerosis and localized scleroderma, alongside a rising...
English
Arabic
Français
Español
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek